Invented by David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang, Immunomedics Inc
The Market for Isolation and Detection of Circulating Cancer Cells that are Positive for Trop-2
Cancer is a leading cause of death worldwide, and early detection plays a crucial role in improving patient outcomes. Traditionally, cancer diagnosis and monitoring have relied on invasive tissue biopsies. However, recent advancements in technology have paved the way for non-invasive methods, such as the isolation and detection of circulating cancer cells (CTCs) in the bloodstream.
One promising biomarker for CTCs is Trop-2, a transmembrane glycoprotein that is overexpressed in various types of cancer, including breast, lung, colorectal, and prostate cancer. Trop-2 has gained significant attention as a potential target for cancer therapy and diagnosis due to its high expression levels in cancer cells and limited expression in normal tissues.
The market for isolation and detection of CTCs that are positive for Trop-2 is rapidly growing, driven by the increasing demand for non-invasive cancer diagnostics and personalized medicine. The ability to detect and analyze CTCs provides valuable information about the disease’s progression, treatment response, and potential for metastasis.
Several technologies and platforms have been developed to isolate and detect CTCs positive for Trop-2. These include immunomagnetic separation, microfluidics-based devices, and polymerase chain reaction (PCR) techniques. Immunomagnetic separation utilizes magnetic beads coated with Trop-2 antibodies to selectively capture and isolate CTCs from blood samples. Microfluidics-based devices use microchannels and specific surface coatings to capture CTCs based on their physical properties, such as size and deformability. PCR techniques involve amplifying and detecting Trop-2 gene expression in CTCs using specific primers and probes.
The market for these technologies is driven by several factors. Firstly, the rising incidence of cancer globally has created a significant demand for accurate and reliable cancer diagnostics. Secondly, the limitations of traditional tissue biopsies, such as invasiveness, limited sampling, and potential for sampling errors, have fueled the need for non-invasive methods like CTC detection. Additionally, the ability to monitor treatment response and detect minimal residual disease using CTCs has attracted interest from clinicians and researchers.
Furthermore, the market for isolation and detection of CTCs positive for Trop-2 is also influenced by the increasing focus on personalized medicine. Trop-2 expression levels can vary among patients and even within different tumor subtypes. Therefore, the ability to identify and analyze CTCs positive for Trop-2 can help tailor treatment strategies and improve patient outcomes.
Despite the promising potential of CTC detection, there are still challenges to overcome. CTCs are rare and heterogeneous, making their isolation and detection technically demanding. Additionally, the standardization of protocols and the validation of assays are necessary to ensure reproducibility and accuracy across different laboratories and platforms.
In conclusion, the market for isolation and detection of circulating cancer cells that are positive for Trop-2 is rapidly expanding. The demand for non-invasive cancer diagnostics, personalized medicine, and the ability to monitor treatment response has fueled the growth of this market. As technology continues to advance and protocols become standardized, the isolation and detection of CTCs positive for Trop-2 hold great promise in improving cancer diagnosis, treatment, and patient outcomes.
The Immunomedics Inc invention works as follows
Described are compositions and techniques for using anti-Trop-2 antibody or antigen-binding fraction thereof to isolate and enrich circulating tumor cells from patients who have a Trop-2-positive cancer. The antibody used is preferably an RS7 antibody, 162-46.2 antibody, or MAB650. “The compositions and methods can be used to diagnose, treat and/or detect metastatic Trop-2+ tumors such as those in the breast, ovarian or cervical cancers.
Background for Isolation and detection of circulating cancer cells that are positive for trop-2
Field of Invention
Cell Binding assay of Anti-Trop-2 Antibodies”.
Blood Samples: Collection and Storage
Spiking Cancer Cells in Blood from Healthy Donors
Isolation and Characterization of Epithelial Cancer cells from Spiked Blood Samples Using a Magnetic Device”.
Isolation and Characterization of Epithelial Cancer cells from Spiked Blood Samples Without the Use of Magnetic Devices
Detection and quantification of epithelial cancer cells from spiked blood samples without prior enrichment
Detection and Analysis of Epithelial Carcinoma Cells in Spiked Blood Samples Using a Construct that Targets both Trop-2 & EGFR
Example 8Click here
to view the patent on Google Patents.